

Quantifying "rewiring" of TF-Gene Network



Rewiring rate = $\frac{1}{C \times \text{Time divergence}}$

TF or Kinase network C = $\operatorname{Reg} \operatorname{CNs} \times (\operatorname{Reg} \operatorname{CNs-1}) + \operatorname{Reg} \operatorname{GNs} \times (\operatorname{Reg} \operatorname{GNs-1}) + \operatorname{Reg} \operatorname{LNs} \times (\operatorname{Reg} \operatorname{LNs-1})$ +Reg CNs \times Tar CNs +Reg GNs \times Tar GNs +Reg LNs \times Tar LNs $+ \text{Reg CNs} \times (\text{Tar GNs} + \text{Tar LNs}) + \text{Tar CNs} \times (\text{Reg GNs} + \text{Reg LNs})$


- LNs and GNs
- redundant edges if two networks are both fully connected
- **Rewiring-Score_{TF}** = R_{TF} / C_{TF}
- $(CN_{GENE} + LN_{GENE})$




• **R_{TF}** - Total number of rewired edges (R) between two networks: union of edges between pairs of CNs that only present in one network and all edges involving

• C_{TF} - Total number of possible edges (C) in the two networks: number of non-

CTF = CNTF X (CNGENE+GNGENE+LNGENE) + GNTF X (CNGENE + GNGENE) + LNTF X





	TF		GENE	
CN	29	67.4%	28	70.0%
GN	9	20.9%	8	20.0%
LN	5	11.6%	4	10.0%
common edge	82		46.6%	
rewired CN	47		26.7%	
rewired GN or LN	47		26.7%	


TIP network is too sparse!

TIP TF-TF network






GM12878



TIP

K562



TF	rScore	Literature
JUND	0.8060	"a double-edged sword in tu target genes. Precise contro differentiation, proliferation a
RCOR1	0.7015	An RCOR1 loss-associated
REST	0.5821	A genetic screen for candida neuronal genes in non-neuro neural plasticity, tumour sup
MYC	0.5672	The MYC oncogene contribution transformation and acute lyr
MTA2	0.5522	MTA2 is a member of the me remodeling and histone dea link between nuclear and cy
TBL1XR1	0.5373	TBL1XR1 mutations detected TBL1XL1 activity is probably
ZBTB33	0.5075	ZBTB33 has been mapped to the NCBI, deletion or translo cancer, and in acute myelob
HDGF	0.4776	HDGF is an important regulation angiogenesis and metastasi localizations where it interactions serum of some cancers.
NRF1	0.4776	c-MYC apoptotic function is
GABPA	0.4776	GABP transcription factor is

		TF	GENE	
CN	61	91.0%	66	98.5%
GN	4	6.0%	0	0.0%
LN	2	3.0%	1	1.5%
common edge	2886		67.9%	
rewired CN	1235		29.0%	
rewired GN or LN	131		3.1%	

umorigenesis"; JunD is a versatile AP-1 transcription factor that can activate or repress a diverse collection of ol of junD expression and JunD protein-protein interactions modulate tumor angiogenesis, cellular and apoptosis.; Whereas c-JUN is oncogenic, JUNB and JUND can have anti-oncogenic effects.

d gene expression signature identifies a prognostically significant DLBCL subgroup

late tumor suppressors identifies REST; REST/NRSF was first identified as a transcriptional repressor of ronal cells. Recent studies have now revealed seemingly paradoxical roles for REST/NRSF in neurogenesis, ppression and cancer progression.

outes to the genesis of many human cancers.; A NOTCH1-driven MYC enhancer promotes T cell development, mphoblastic leukemia

netastasis tumor-associated family of transcriptional regulators and is a central component of the nucleosome acetylation complex. MTA2 acts as a central hub for cytoskeletal organization and transcription and provides a ytoskeletal organization.


ed in our patient cohort are predicted to be monoallelic loss-of-function mutations, suggesting that reduction in ly mechanistically involved in leukemogenesis.

to Xq23 and CTNND1 has been mapped to 11q11. According to the Cancer Chromosomes Entrez database of location of these regions has been reported in a number of solid tumours such as colon, pancreatic and ovarian blastic leukaemia.


lator of a broad range of cancer cell activities and plays important roles in cancer cell transformation, apoptosis, sis. Such a divergent influence of HDGF on cancer cell activities derives from its multiple inter- and sub-cellular cts with a range of different binding partners. Interestingly, high levels of HDGF could be detected in patients'

mediated by NRF-1 target genes

s required for development of chronic myelogenous leukemia via its control of PRKD2




GM12878



K562

GM12878



TSS

K562

